FI62314C - Foerfarande foer framstaellning av terapeutiskt anvaendbara ny 3-((3-alkylisokinol-5-yl)imino)-1,5,10,10a-tetrahydrotia zoo(3,4-b)isokinoliner - Google Patents
Foerfarande foer framstaellning av terapeutiskt anvaendbara ny 3-((3-alkylisokinol-5-yl)imino)-1,5,10,10a-tetrahydrotia zoo(3,4-b)isokinoliner Download PDFInfo
- Publication number
- FI62314C FI62314C FI780182A FI780182A FI62314C FI 62314 C FI62314 C FI 62314C FI 780182 A FI780182 A FI 780182A FI 780182 A FI780182 A FI 780182A FI 62314 C FI62314 C FI 62314C
- Authority
- FI
- Finland
- Prior art keywords
- imino
- formula
- isoquinoline
- tetrahydrothiazolo
- prepared
- Prior art date
Links
- -1 IMINO Chemical class 0.000 title claims description 28
- 238000000034 method Methods 0.000 title claims description 13
- 238000002360 preparation method Methods 0.000 title claims description 7
- 101000740162 Homo sapiens Sodium- and chloride-dependent transporter XTRP3 Proteins 0.000 title 1
- 102100037189 Sodium- and chloride-dependent transporter XTRP3 Human genes 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 34
- 150000003839 salts Chemical class 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 claims description 6
- 229910052801 chlorine Inorganic materials 0.000 claims description 6
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- DTVYNUOOZIKEEX-UHFFFAOYSA-N 5-aminoisoquinoline Chemical compound N1=CC=C2C(N)=CC=CC2=C1 DTVYNUOOZIKEEX-UHFFFAOYSA-N 0.000 claims description 3
- 230000002378 acidificating effect Effects 0.000 claims description 3
- 150000002537 isoquinolines Chemical class 0.000 claims description 3
- 150000001450 anions Chemical class 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 14
- 241000700159 Rattus Species 0.000 description 13
- 239000013078 crystal Substances 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 10
- 239000003960 organic solvent Substances 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 8
- QPGUKSFXJCUUMG-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinolin-3-ylmethyl hydrogen sulfate Chemical compound C1=CC=C2CNC(COS(=O)(=O)O)CC2=C1 QPGUKSFXJCUUMG-UHFFFAOYSA-N 0.000 description 7
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 7
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 7
- DOJPVHCIGMTXAG-UHFFFAOYSA-N 3-methylsulfanyl-1,5,10,10a-tetrahydro-[1,3]thiazolo[3,4-b]isoquinolin-4-ium Chemical compound C1C2=CC=CC=C2CC2[N+]1=C(SC)SC2 DOJPVHCIGMTXAG-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 6
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- AWJUIBRHMBBTKR-UHFFFAOYSA-N iso-quinoline Natural products C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- ZSKDXMLMMQFHGW-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinolin-3-ylmethanol Chemical compound C1=CC=C2CNC(CO)CC2=C1 ZSKDXMLMMQFHGW-UHFFFAOYSA-N 0.000 description 4
- RLQZIECDMISZHS-UHFFFAOYSA-N 2-phenylcyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C=CC(=O)C(C=2C=CC=CC=2)=C1 RLQZIECDMISZHS-UHFFFAOYSA-N 0.000 description 4
- MKZBYSNGUDMVDZ-UHFFFAOYSA-N 3-ethylisoquinolin-5-amine Chemical compound C1=CC=C2C=NC(CC)=CC2=C1N MKZBYSNGUDMVDZ-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 230000003187 abdominal effect Effects 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000000679 carrageenan Substances 0.000 description 4
- 229940113118 carrageenan Drugs 0.000 description 4
- 235000010418 carrageenan Nutrition 0.000 description 4
- 229920001525 carrageenan Polymers 0.000 description 4
- 230000008602 contraction Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 125000001841 imino group Chemical group [H]N=* 0.000 description 4
- AWJUIBRHMBBTKR-UHFFFAOYSA-O isoquinolin-2-ium Chemical compound C1=[NH+]C=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-O 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 4
- RKZRSFDITVGOHP-UHFFFAOYSA-N 1,5,10,10a-tetrahydro-[1,3]thiazolo[3,4-b]isoquinoline-3-thione Chemical compound C1=CC=C2CN3C(=S)SCC3CC2=C1 RKZRSFDITVGOHP-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 206010000269 abscess Diseases 0.000 description 3
- 125000004414 alkyl thio group Chemical group 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000155 melt Substances 0.000 description 3
- 229960005190 phenylalanine Drugs 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- WRIZFUVYABPOLN-UHFFFAOYSA-N 2h-isoquinoline-3-thione Chemical compound C1=CC=C2C=NC(S)=CC2=C1 WRIZFUVYABPOLN-UHFFFAOYSA-N 0.000 description 2
- RIXACYCTQSOLND-UHFFFAOYSA-N 3-butylisoquinolin-5-amine Chemical compound C1=CC=C2C=NC(CCCC)=CC2=C1N RIXACYCTQSOLND-UHFFFAOYSA-N 0.000 description 2
- ZQLKOMXEZYQQBJ-UHFFFAOYSA-N 3-methylisoquinolin-5-amine Chemical compound C1=CC=C2C=NC(C)=CC2=C1N ZQLKOMXEZYQQBJ-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- UYDOPYNXEDBOPX-UHFFFAOYSA-N N-(3-ethylisoquinolin-5-yl)-3-(hydroxymethyl)-3,4-dihydro-1H-isoquinoline-2-carbothioamide Chemical compound C(C)C=1N=CC2=CC=CC(=C2C=1)NC(=S)N1CC2=CC=CC=C2CC1CO UYDOPYNXEDBOPX-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 150000002540 isothiocyanates Chemical class 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- IHCCLXNEEPMSIO-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 IHCCLXNEEPMSIO-UHFFFAOYSA-N 0.000 description 1
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical compound [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- NXPGJFIKBCDNOJ-UHFFFAOYSA-N 3-octylisoquinolin-5-amine Chemical compound C1=CC=C2C=NC(CCCCCCCC)=CC2=C1N NXPGJFIKBCDNOJ-UHFFFAOYSA-N 0.000 description 1
- SSIPWNMRZDPBHH-UHFFFAOYSA-N 3-propylisoquinolin-5-amine Chemical compound C1=CC=C2C=NC(CCC)=CC2=C1N SSIPWNMRZDPBHH-UHFFFAOYSA-N 0.000 description 1
- ASNHGEVAWNWCRQ-UHFFFAOYSA-N 4-(hydroxymethyl)oxolane-2,3,4-triol Chemical compound OCC1(O)COC(O)C1O ASNHGEVAWNWCRQ-UHFFFAOYSA-N 0.000 description 1
- DFGKGUXTPFWHIX-UHFFFAOYSA-N 6-[2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]acetyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)C1=CC2=C(NC(O2)=O)C=C1 DFGKGUXTPFWHIX-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 description 1
- 229930182832 D-phenylalanine Natural products 0.000 description 1
- DDLUPGYXJUGRNH-UHFFFAOYSA-N N-(3-octylisoquinolin-5-yl)-1,5,10,10a-tetrahydro-[1,3]thiazolo[3,4-b]isoquinolin-3-imine Chemical compound C(CCCCCCC)C=1N=CC2=CC=CC(=C2C=1)N=C1SCC2N1CC=1C=CC=CC=1C2 DDLUPGYXJUGRNH-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- FIWILGQIZHDAQG-UHFFFAOYSA-N NC1=C(C(=O)NCC2=CC=C(C=C2)OCC(F)(F)F)C=C(C(=N1)N)N1N=C(N=C1)C1(CC1)C(F)(F)F Chemical compound NC1=C(C(=O)NCC2=CC=C(C=C2)OCC(F)(F)F)C=C(C(=N1)N)N1N=C(N=C1)C1(CC1)C(F)(F)F FIWILGQIZHDAQG-UHFFFAOYSA-N 0.000 description 1
- MVNVXVPOPFEKQD-UHFFFAOYSA-N NC1=C2C=CN=CC2=CC=C1.C(=S)=S Chemical compound NC1=C2C=CN=CC2=CC=C1.C(=S)=S MVNVXVPOPFEKQD-UHFFFAOYSA-N 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 101100173585 Schizosaccharomyces pombe (strain 972 / ATCC 24843) fft1 gene Proteins 0.000 description 1
- TZEYHTCZIQZAPS-UHFFFAOYSA-N [1,3]thiazolo[4,5-h]isoquinoline Chemical class C1=CN=CC2=C(SC=N3)C3=CC=C21 TZEYHTCZIQZAPS-UHFFFAOYSA-N 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- VNWKTOKETHGBQD-AKLPVKDBSA-N carbane Chemical compound [15CH4] VNWKTOKETHGBQD-AKLPVKDBSA-N 0.000 description 1
- QGJOPFRUJISHPQ-NJFSPNSNSA-N carbon disulfide-14c Chemical compound S=[14C]=S QGJOPFRUJISHPQ-NJFSPNSNSA-N 0.000 description 1
- 239000012320 chlorinating reagent Substances 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- GVLGAFRNYJVHBC-UHFFFAOYSA-N hydrate;hydrobromide Chemical compound O.Br GVLGAFRNYJVHBC-UHFFFAOYSA-N 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- MBXNQZHITVCSLJ-UHFFFAOYSA-N methyl fluorosulfonate Chemical compound COS(F)(=O)=O MBXNQZHITVCSLJ-UHFFFAOYSA-N 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012261 resinous substance Substances 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Pain & Pain Management (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7701516 | 1977-01-20 | ||
| FR7701516A FR2378030A1 (fr) | 1977-01-20 | 1977-01-20 | Nouveau derive de l'isoquinoleine, sa preparation et les compositions qui le contiennent |
| FR7739028 | 1977-12-23 | ||
| FR7739028A FR2412545A1 (fr) | 1977-12-23 | 1977-12-23 | Nouveaux derives de l'isoquinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI780182A7 FI780182A7 (fi) | 1978-07-21 |
| FI62314B FI62314B (fi) | 1982-08-31 |
| FI62314C true FI62314C (fi) | 1982-12-10 |
Family
ID=26219809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI780182A FI62314C (fi) | 1977-01-20 | 1978-01-20 | Foerfarande foer framstaellning av terapeutiskt anvaendbara ny 3-((3-alkylisokinol-5-yl)imino)-1,5,10,10a-tetrahydrotia zoo(3,4-b)isokinoliner |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US4153698A (no) |
| JP (1) | JPS5914037B2 (no) |
| AR (2) | AR217460A1 (no) |
| AT (1) | AT361481B (no) |
| AU (1) | AU510044B2 (no) |
| CA (1) | CA1091674A (no) |
| CH (1) | CH633010A5 (no) |
| CS (2) | CS195349B2 (no) |
| DE (1) | DE2802453C3 (no) |
| DK (1) | DK143343C (no) |
| ES (2) | ES466192A1 (no) |
| FI (1) | FI62314C (no) |
| GB (1) | GB1574281A (no) |
| GR (1) | GR61726B (no) |
| HU (1) | HU174219B (no) |
| IE (1) | IE46375B1 (no) |
| IL (1) | IL53841A (no) |
| LU (1) | LU78895A1 (no) |
| NL (1) | NL7800383A (no) |
| NO (1) | NO780202L (no) |
| NZ (1) | NZ186282A (no) |
| OA (1) | OA05859A (no) |
| PT (1) | PT67545B (no) |
| SE (1) | SE7800681L (no) |
| SU (2) | SU730309A3 (no) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU797580A3 (ru) * | 1977-11-10 | 1981-01-15 | Рон-Пуленк Эндюстри (Фирма) | Способ получени производных изохино-лиНА, иХ СОлЕй, РАцЕМАТОВ или ОпТичЕС-КиХ изОМЕРОВ |
| FR2456098A2 (fr) * | 1977-12-23 | 1980-12-05 | Rhone Poulenc Ind | Nouveaux derives de l'isoquinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent |
| NL7908655A (nl) * | 1978-12-07 | 1980-06-10 | Rhone Poulenc Ind | Nieuwe thienopyridine-derivaten, de bereiding ervan, alsmede farmaceutische preparaten, die de nieuwe derivaten bevatten. |
| GB2048880A (en) * | 1979-05-09 | 1980-12-17 | Rhone Poulenc Ind | Isoquinoline derivatives |
| FR2456111A1 (fr) * | 1979-05-09 | 1980-12-05 | Rhone Poulenc Ind | Nouveaux derives de l'indole, leur preparation et les medicaments qui les contiennent |
| NZ195721A (en) * | 1979-12-04 | 1982-09-14 | Rhone Poulenc Ind | Thiazolo(3,4-b)isoquinoline derivatives and pharmaceutical compositions |
| US4269842A (en) * | 1979-12-05 | 1981-05-26 | Rhone-Poulenc Industries | Method for treating rhinoviral complaints |
| US6582728B1 (en) * | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| OA05403A (fr) * | 1975-08-06 | 1981-02-28 | Rhone Poulenc Ind | Nouveaux dérivés de la thiazolo [3,4-b] isoquinoléine et leur procédé de préparation. |
-
1978
- 1978-01-12 NL NL7800383A patent/NL7800383A/xx not_active Application Discontinuation
- 1978-01-17 CS CS78323A patent/CS195349B2/cs unknown
- 1978-01-17 CS CS785983A patent/CS195350B2/cs unknown
- 1978-01-17 OA OA56380A patent/OA05859A/xx unknown
- 1978-01-18 GR GR55196A patent/GR61726B/el unknown
- 1978-01-18 IL IL53841A patent/IL53841A/xx unknown
- 1978-01-19 SU SU782567352A patent/SU730309A3/ru active
- 1978-01-19 LU LU78895A patent/LU78895A1/xx unknown
- 1978-01-19 CH CH56178A patent/CH633010A5/fr not_active IP Right Cessation
- 1978-01-19 CA CA295,296A patent/CA1091674A/fr not_active Expired
- 1978-01-19 AT AT39378A patent/AT361481B/de not_active IP Right Cessation
- 1978-01-19 HU HU78RO958A patent/HU174219B/hu unknown
- 1978-01-19 PT PT67545A patent/PT67545B/pt unknown
- 1978-01-19 GB GB2241/78A patent/GB1574281A/en not_active Expired
- 1978-01-19 DK DK27178A patent/DK143343C/da not_active IP Right Cessation
- 1978-01-19 SE SE7800681A patent/SE7800681L/xx unknown
- 1978-01-19 NO NO780202A patent/NO780202L/no unknown
- 1978-01-20 FI FI780182A patent/FI62314C/fi not_active IP Right Cessation
- 1978-01-20 JP JP53005113A patent/JPS5914037B2/ja not_active Expired
- 1978-01-20 DE DE2802453A patent/DE2802453C3/de not_active Expired
- 1978-01-20 AU AU32611/78A patent/AU510044B2/en not_active Expired
- 1978-01-20 IE IE126/78A patent/IE46375B1/en unknown
- 1978-01-20 NZ NZ186282A patent/NZ186282A/xx unknown
- 1978-01-20 US US05/871,136 patent/US4153698A/en not_active Expired - Lifetime
- 1978-01-20 ES ES466192A patent/ES466192A1/es not_active Expired
- 1978-01-20 AR AR270785A patent/AR217460A1/es active
- 1978-04-07 ES ES468630A patent/ES468630A1/es not_active Expired
-
1979
- 1979-02-05 AR AR275407A patent/AR219963A1/es active
- 1979-02-08 SU SU792720496A patent/SU776560A3/ru active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI61896B (fi) | Foerfarande foer framstaellning av antiinflammatoriska foer reumavaord laempliga och antitrombotiska 4-hydroxi-2h-1,2-benzodiazin-3-karboxamid-1,1-dioxider | |
| ES2276530T3 (es) | Azabiciclos qu4e modelan la inhibicion de la adherencia celular. | |
| Gray et al. | Phencyclidine-like effects of tetrahydroisoquinolines and related compounds | |
| FI100969B (fi) | Menetelmä valmistaa terapeuttisesti aktiivista pyratsolo£1,5-a|pyridii niyhdistettä | |
| PT87988B (pt) | Processo para a preparacao de diazois e de composicoes farmaceuticas que os contem | |
| FI62314C (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara ny 3-((3-alkylisokinol-5-yl)imino)-1,5,10,10a-tetrahydrotia zoo(3,4-b)isokinoliner | |
| FI63416C (fi) | Som soetningsmedel anvaendbara 4,5-dimetyl- och 5-metyl-tieno(3,2-d)isotiatsol-3(2h)-on-1,1-dioxider och deras framstaellningsfoerfarande | |
| KR100204633B1 (ko) | 신규 벤즈이미다졸 유도체 그의 제조방법 그의 신규 중간체 그의 약물 용도 및 그를 함유하는 제약 조성물 | |
| FI63029B (fi) | Foerfarande foer framstaellning av ulcushaemmande n-substituerade 5,11-dihydro-(piperazin-1'-yl-alkanoyl)-6h-pyrido(2,3-b)(1,4)-benzodiazepin-6-on-derivater | |
| DE68918257T2 (de) | 4,5,6,7-Tetrahydrobenzimidazol-Derivate und ihre Herstellung. | |
| Kashaw et al. | Design, synthesis and potential CNS activity of some novel 1-(4-substituted-phenyl)-3-(4-oxo-2-propyl-4H-quinazolin-3-yl)-urea | |
| FI63588B (fi) | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara heterosyklylimino-1,6,11,11a-tetrahydro(1,3-tiazino)(3,4-b)isokinoliner | |
| KR20050057654A (ko) | 고컨덕턴스의 칼슘-활성화된 ｋ 채널 개방제 | |
| JPH0227969B2 (no) | ||
| FI82462C (fi) | Foerfarande foer framstaellning av terapeutiskt verksamma indolderivat. | |
| WO1994017075A1 (en) | Diazepin derivatives and antiviral compositions | |
| FI69077C (fi) | Foerfarande foer framstaellning av tieno-(2,3-c) och (3,2-c) pyridinderivat | |
| PL144860B1 (en) | Method of obtaining novel derivatives of iminothiasolidyne | |
| PL116688B1 (en) | Process for the preparation of trinuclear compounds with nitrogen atom in nodal position | |
| US4350698A (en) | Antiallergic imidosulfamides | |
| DK150158B (da) | Analogifremgangsmaade til fremstilling af 4-phenylthieno-(2,3-c)piperidiner eller fysiologisk acceptable syreadditionssalte deraf | |
| NZ206305A (en) | Benzazepine and benzodiazepine derivatives and pharmaceutical compositions | |
| FI61190C (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara 6-(piperazin-1-yl)karbonyloxi-8-oxo-3,4,7,8-tetrahydro-2h 6h-(1,4)-ditiepino(2,3-c)-pyrrolderivat | |
| FI63569C (fi) | Foerfarande foer framstaellning av farmaceutiskt anvaendbara 6,11-dihydro-11-oxodibenz(b e)oxepinalkylkarboxylsyror och deas estrar | |
| NL8205038A (nl) | Esters van 4-hydroxymethyl-1-ftalazonderivaten en zouten daarvan. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM | Patent lapsed |
Owner name: RHONE- POULENC INDUSTRIES |